Dupilumab has demonstrated significant and clinically meaningful improvements in disease activity and severity among patients with prurigo nodularis (PN), a chronic dermatological condition characterized by intensely pruritic nodules. A post hoc analysis of pooled data from the Phase III PRIME and PRIME2 trials assessed treatment response using the Prurigo Activity and Severity (PAS) score.
At 24 weeks, dupilumab-treated patients experienced a significantly greater reduction in PAS score compared with placebo. Nearly 70% of patients receiving dupilumab achieved a clinically meaningful response, defined as a ≥3-point reduction in PAS score, compared with just over a quarter of those on placebo.
Further analysis reinforced these findings, showing a significantly greater proportion of patients treated with dupilumab achieved ≤25% of lesions with excoriations or crusting. More than half of dupilumab-treated patients reached ≥75% healed lesions, compared with fewer than one in five in the placebo group.
These results highlight dupilumab’s robust effect not only on overall disease severity but also on key clinical features associated with disease burden and healing. The findings support dupilumab as an effective therapeutic option for patients with PN, providing further evidence for targeted biologic therapy in managing difficult-to-treat inflammatory skin diseases.